36 completed. 36 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Completed 36 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Chronic Urticaria: new trials by email Literature Review of Chronic Urticaria trials Research Report on Chronic Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) EVO756, Placebo control - Chronic Spontaneous Urticaria | Phase 2 | Completed | Evommune, Inc. | 182 | 2025-03-20 | 2026-07-01 |
| A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria Oral EVO756 300 mg QD, Oral EVO756 50 mg BID - Chronic Inducible Urticaria | Phase 2 | Completed | Evommune, Inc. | 30 | 2024-08-14 | 2026-05-19 |
| Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment LP-003, Placebo, Omalizumab - Chronic Spontaneous Urticaria | Phase 2 | Completed | Longbio Pharma | 202 | 2024-01-26 | 2026-10-21 |
| Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Briquilimab, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Completed | Jasper Therapeutics, Inc. | 87 | 2023-11-29 | 2026-08-06 |
| Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Povorcitinib, Placebo - Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Completed | Incyte Corporation | 136 | 2023-07-31 | 2026-03-12 |
| A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome VTX2735 - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zomagen Biosciences Ltd. | 7 | 2023-03-18 | 2025-03-10 |
| A Study of CDX-0159 in Patients With Chronic Inducible Urticaria barzolvolimab, Matching Placebo - Chronic Inducible Urticaria | Phase 2 | Completed | Celldex Therapeutics | 196 | 2022-06-28 | 2025-11-06 |
| A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria TAS5315 Dose 1, TAS5315 Dose 2, TAS5315 Dose 3 - Chronic Spontaneous Urticaria | Phase 2 | Completed | Taiho Pharmaceutical Co., Ltd. | 126 | 2022-06-28 | 2024-08-07 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) ZYIL1 capsule - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zydus Lifesciences Limited | 3 | 2022-06-01 | 2022-07-11 |
| A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria barzolvolimab, Matching Placebo - Chronic Spontaneous Urticaria | Phase 2 | Completed | Celldex Therapeutics | 208 | 2022-05-19 | 2025-03-26 |
| Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine rilzabrutinib, placebo - Chronic Spontaneous Urticaria | Phase 2 | Completed | Sanofi | 160 | 2021-11-24 | 2026-08-06 |
| Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) DFV890 - Familial Cold Autoinflammatory Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 4 | 2021-09-20 | 2024-10-09 |
| Modified Xiao-Feng Powder for Chronic Urticaria Modified Xiao-Feng Powder + Antiallergics, Placebo + Antiallergics - Chronic Urticaria | Phase 2 | Completed | Prof. Lin Zhixiu | 58 | 2021-08-15 | 2026-07-27 |
| Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab - Chronic Spontaneous Urticaria | Phase 2 | Completed | Amgen | 183 | 2021-04-15 | 2025-04-09 |
| Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients CBD - Chronic Spontaneous Urticaria | Phase 2 | Completed | Stero Biotechs Ltd. | 15 | 2020-02-01 | 2024-04-18 |
| An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU LOU064 - Chronic Spontaneous Urticaria | Phase 2 | Completed | Novartis Pharmaceuticals | 229 | 2019-10-24 | 2024-06-20 |
| This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3 - Chronic Spontaneous Urticaria | Phase 2 | Completed | Novartis Pharmaceuticals | 311 | 2019-06-06 | 2022-04-29 |
| A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases KPL-716, Placebo - Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus | Phase 2 | Completed | Genentech, Inc. | 58 | 2019-05-29 | 2025-03-18 |
| Dupilumab in Chronic Spontaneous Urticaria Dupilumab, Placebo - Chronic Spontaneous Urticaria, Recurrent Angioedema | Phase 2 | Completed | Charite University, Berlin, Germany | 72 | 2018-11-12 | 2022-02-02 |
| Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) Ligelizumab, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Completed | Novartis Pharmaceuticals | 49 | 2018-08-01 | 2026-01-13 |
Showing 20 of 36. Sign in to see all of them.
Urticaria (8) · Cryopyrin-Associated Periodic Syndromes (6) · Pruritus (5) · Urticaria, Solar (3) · Angioedema (2) · Bronchiolitis Obliterans Syndrome (2) · Chronic Inducible Urticaria (2) · Chronic Disease (1) · Epilepsy, Idiopathic Generalized (1) · Erythema (1) · Familial Mediterranean Fever (1) · Fever (1) · Hypersensitivity (1) · Immune System Diseases (1)
Disease Attributes (36) · Hypersensitivity, Immediate (36) · Pathological Conditions, Signs and Symptoms (36) · Skin and Connective Tissue Diseases (36) · Chronic Disease (35) · Hypersensitivity (35) · Immune System Diseases (35) · Pathologic Processes (35) · Skin Diseases (35) · Skin Diseases, Vascular (35) · Urticaria (28) · Chronic Inducible Urticaria (9) · Cold Urticaria (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)
Omalizumab (9) · ligelizumab (3) · rilonacept (2) · AK002 (1) · AZD1981 (1) · Anti-Allergic Agents (1) · BID protein, human (1) · Clemastine (1) · Diphenhydramine (1) · Immunoglobulins, Intravenous (1) · Loratadine (1) · ZYIL1 (1) · afamelanotide (1) · bilastine (1) · canakinumab (1)
Novartis Pharmaceuticals (8) · Celldex Therapeutics (2) · Centre Hospitalier Universitaire de Besancon (2) · Charite University, Berlin, Germany (2) · Evommune, Inc. (2) · Genentech, Inc. (2) · Allakos Inc. (1) · Amgen (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Clinuvel Pharmaceuticals Limited (1) · Faes Farma, S.A. (1) · Incyte Corporation (1) · Insel Gruppe AG, University Hospital Bern (1) · Jasper Therapeutics, Inc. (1) · Johns Hopkins University (1)
Germany (18) · United States (17) · Spain (11) · Canada (8) · Japan (8) · France (7) · Poland (7) · Russia (6) · United Kingdom (6) · Hungary (5) · Argentina (4) · Australia (4) · Greece (4) · Taiwan (4) · Belgium (3)
Dr Deven Parmar, MD (1) · Gunilla Hedlin, Prof. Dr. (1) · Henrik Rasmussen, MD, PhD (1) · Henrik Sonnergren, MD, PhD (1) · Karin Rosen, M.D., Ph.D. (1) · Lennart Nordvall, Prof. Dr (1) · Lesley Rhodes, M.D. (1) · Manuelle Viguier, Dr (1)
PMID 34773261, PMID 36440464, PMID 18668591, PMID 21356079, PMID 22583335, PMID 29974963, PMID 31577874, PMID 35869554, PMID 37492920, PMID 37866460, PMID 40266575, PMID 41747871
2017 (2), 2009 (1), 2014 (1), 2015 (1), 2018 (1), 2019 (1), 2023 (1)